RNA delivery is an attractive strategy to achieve transient gene expression in research projects and in cell-or gene-based therapies. Despite significant efforts investigating vector-directed RNA transfer, there is still a requirement for better efficiency of delivery to primary cells and in vivo. Retroviral platforms drive RNA delivery, yet retrovirus RNA-packaging constraints limit gene transfer to two genome-molecules per viral particle. To improve retroviral transfer, we designed a dimerization-independent MS2-driven RNA packaging system using MS2-Coat-retrovirus chimeras. The engineered chimeric particles promoted effective packaging of several types of RNAs and enabled efficient transfer of biologically active RNAs in various cell types, including human CD34 + and iPS cells. Systemic injection of high-titer particles led to gene expression in mouse liver and transferring Cre-recombinase mRNA in muscle permitted widespread editing at the ROSA26 locus. We could further show that the VLPs were able to activate an osteoblast differentiation pathway by delivering RUNX2-or DLX5-mRNA into primary human bone-marrow mesenchymal-stem cells. Thus, the novel chimeric MS2-lentiviral particles are a versatile tool for a wide range of applications including cellular-programming or genome-editing.
INTRODUCTION
Achieving curative gene therapy for genetic diseases has been a remarkable reward after 30 years of bench-to-bedside transfer. 1 We now foresee the advent of a medical revolution with cellular reprogramming and genome editing, alone or in combination. 1 In the cell and gene therapy era, the need for improved targeted expression of cellular factors is critical. 2, 3 Moreover, for biological and safety reasons, the lifelong persistence of foreign genetic information is not desirable in many cases. 4 Protein delivery has recently allowed transient expression in various cell types. 5, 6 RNA transfer also remains relevant and has been extensively developed with chemical, viral, and biophysical techniques. Importantly, RNA transfer allows transient expression and tuneable control. 7 By exploiting the mRNA nature of the retroviral genome, 8 Baum and others converted murine oncoretroviruses into RNA transfer vectors, [9] [10] [11] which was then extended to other retroviruses. 12, 13 mRNA delivery from retroviral vectors involved the natural Ψ sequence and knockdown of molecular determinants for reverse transcription, or modification of cellular mRNA by adding the retroviral packaging sequence. 10, 14 Hence, these platforms feature viral constraints in genome recruitment and the use of the canonical viral-packaging sequence restrains delivery to no more than two RNAs per particle. 8 An alternative packaging system not relying on the dimerization of the genomic RNA could improve the efficiency of transduction. To improve RNA transfer by retroviral platforms, we designed novel chimeric particles that rely on the well-characterized interaction between bacteriophage MS2-Coat protein and the MS2-RNA genome. 15 Through the physiological recognition of its cognate RNA, MS2-Coat governs the replication-to-assembly transition during the leviviridae lytic cycle. 16 This interaction involves a 19-nt stemloop structure within the phage replicase gene. 17 MS2-Coat protein systems have wide application for studying RNA biology and fluorescent MS2-Coat-protein have been used to track cellular RNAs. 18, 19 Recently, MS2-Coat was used for semisynthetic gene delivery. 20, 21 Here, we challenged retroviral plasticity to tolerate insertion of an MS2-Coat domain allowing for heterogeneous RNA recruitment. 6 Several retroviral sequences were amenable to modification in retroviral-based vectors. 6, 22 In this study, we evaluated the capacity to transfer MS2-Coat-binding RNAs from our redesigned HIV-1-derived vectors. Having shown particle formation, and confirmed by quantitative assays that MS2 chimeric RNA lentiviral particles (MS2RLPs) contained significantly more than two RNAs, we achieved visible efficient transfer of functional RNAs in vitro, with no need for selection. Concentrated chimeric particles led to significant liver and muscle transduction in vivo. Finally, lentiviral cargoes containing mRNAs coding osteogenic transcription factors triggered a shift in the transcription program of primary bone-marrow mesenchymal stem cells (MSCs).
ReSUlTS
Chimeric MS2-Coat-lentiviral particles promote efficient packaging of MS2-RNA To date, because the natural mode of packaging implies RNA dimerization within Ψ, the number of RNAs within each particle is limited to 2. 8, 23 To increase retroviral mRNA delivery, we engineered dimerization-independent RNA recruitment by exploiting the specific interaction between the phage MS2-Coat protein and MS2 RNA genome in a lentiviral context. For this, we needed to design two components, the biologically active RNA to be recruited and the recruiting particle. The minimal 19-nt stem-loop sequence required for interaction between the phage MS2-Coat protein and MS2 RNA was introduced in multiple copies 24, 25 into a eukaryotic expression vector. We first cloned the stem-loop at the 3' end of a reporter gene, luciferase (Luc_MS2_12X) ( Figure 1a) . Next, to obtain the packaging of MS2-stem-loop containing RNA into a particle, we engineered an HIV-1-based complementation vector. 26 HIV-1 recruits its genomic RNA via a complex process, 8, 23 in which the viral nucleocapsid protein (NC) has a central role. Because NC has several other functions in HIV-1 biology, we could not simply replace it (for review, see ref. 27 ). HIV-1 NC contains two zinc finger domains (ZF1 and ZF2) involved in RNA interaction; ZF2 was shown to be dispensable for particle budding 22 and was thus selected for modification. We first generated a reference and negative control construct (p8.74 ΔZF, Figure 1a ) and next introduced in-frame the sequence encoding bacteriophage MS2-Coat protein, replacing ZF2 (p8.74 ΔZF_MS2-coat) ( Figure 1a ).
To determine whether this system could allow MS2-lentiviral particle (MS2RLPs) formation and mRNA recruitment, the Luc_MS2_12X vector was transfected along with each HIV-1 packaging construct (p8.74, p8.74 ΔZF, or p8.74 ΔZF_MS2coat). In the first experiments, MS2RLPs were pseudotyped by the 4070A amphotropic envelope, preventing unspecific release of cellular vesicles formed by the pantropic VSV-G. 28 Measurements of the concentration of CAp24 in the supernatant from control and MS2RLPs transfected cells by enzyme-linked immunosorbent assay (ELISA) suggested that the packaging constructs supported particle formation (data not shown). This was confirmed by electron microscopy showing particles in the medium from transfected cells (Figure 1b) . Morphologically, the majority of MS2RLPs appeared similar to conventional lentiviral vectors with only a slight change in shape and size (Figure 1b ). Of note, these differences were associated with the presence of unprocessed Gag precursor in MS2RLPs (Supplementary Figure S1a) .
Next, we analyzed uptake of luciferase-mRNA into the MS2RLPs. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) confirmed the specific recruitment of Luc_MS2_12X mRNA into MS2RLPs ( 
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Packaging sequence P1  P2  CA  MA  NC  P6 POL   ZF1 ZF2   P1  P2  CA  MA  NC  P6 POL   ZF1   MA  P1  P2  CA  NC  P6 POL   ZF1   MS2-coat   p8.74 (WT) p8.74 ∆ZF (∆ZF) p8.74 ∆ZF_MS2coat (∆ZF_MS2coat) a 19-nt stem-loop. Importantly, because the amount of luciferase RT-qPCR mRNA was normalized to that of particle load measured by CAp24, the higher signal obtained for MS2RLP-Luc suggested that MS2RLPs packaged more RNA molecules per particle than the wildtype Ψ-dependent lentiviral system ( Figure 1c , compare sample 1 and 6). Since MS2RLPs had a shape close to that of regular lentiviral vectors (Figure 1b) , we hypothesized that the CAp24 concentration was proportional to the number of particles released both for the standard lentiviral vectors and for MS2RLP. This was confirmed by a western blot analysis of MS2RLP and integrative-lentiviral (ILV) particles showing that both particles contained detectable CAp24, while MS2RLP had a higher proportion of Gag precursor (Supplementary Figure S1a) . To accurately estimate the MS2RLP RNA contents, we designed a dilution-based method (see Materials and Methods and Supplementary Figure S1b) . These results allowed us to show that MS2RLP contained around 2.8 times more RNA than a standard vector (Supplementary Figure S1b) . Considering that Ψ-dependent vectors contained two viral genomes, we estimated the number of RNA molecules per MS2RLP to be around 5 to 6 ( Figure 1c and Supplementary Figure S1b) .
RNA transfer vectors
Kinetic of MS2RLP-delivered RNA expression We further showed that MS2RLPs drove rapid and efficient gene expression in vitro. To assess the functionality of the packaged MS2-12X mRNA, we assayed whether packaged RNAs enabled luciferase expression. Filtered supernatants, harvested 48 and 72 hours after transfection, were used to transduce 293T cells. Luciferase activity was measured 3 hours after transduction (Figure 2a , dark blue bars, samples 1-6). Luciferase expression was detected in cells transduced with MS2RLPs, but only at background levels in wildtype or ΔZF lentiviral control constructs (Figure 2a , dark blue bars; 4, 5 compared to 6), demonstrating that packaged mRNAs were functional. To ensure that the detected luciferase activity was due to mRNA transfer and subsequent translation, and not to pseudotransduction, the passive transfer of luciferase protein, we pretreated recipient 293T cells with 3 µg/ml of the translation inhibitor puromycin at 1 hour before transduction (Figure 2a , light blue bars).
Puromycin-treated cells showed only background luciferase activity as compared with nontreated cells (Figure 2a, Figure S2a) . Transfection of pLuc conferred detectable luciferase expression only after 8 hours and peaked at 24 hours, whereas IDLV or ILV conferred detectable luciferase expression only at 24 hours after transfer ( Figure 2b ; panels 2, 4, and 5). Therefore, the RNA delivered by MS2RLPs was more rapidly expressed than the plasmid-driven gene expression, conventional or nonintegrating lentiviral vectors. This showed that MS2RLPs allowed for rapid and high gene-expression.
EGFP
We next evaluated MS2RLP functionality with a green fluorescent protein (GFP)-based reporter system using MS2-12X-GFP RNA (MS2RLP-GFP). For comparison, MS2RLP and GFP expressing IDLV particles were produced and concentrated side by side and identical volumes of vector supernatants were used to transduce human hematopoietic cord blood CD34 + cells at several time points after thawing (Figure 2c1 ). For cells transduced several times at 12 hours interval, more than 90% of the cells were GFP-positive cells with both vectors (Figure 2c1) . Interestingly, the proportion of GFP-positive cells was twice higher with MS2RLP-GFP than with IDLV-GFP when cells were transduced immediately after thawing (Figure 2c1,2c2 ). This certainly reflected the need for CD34 + cells to be activated before efficient transduction.
29 MS2RLP-GFP led to higher fluorescence intensity at early time points, but it tended to decrease slightly more rapidly than for IDLV-GFP (Figure 2c1) .
In an effort to compare transduction and expression efficacy from MS2RLP-GFP to that obtained with other transfection methods, we used electroporation, one of the only methods capable of allowing efficient transfection of human primary CD34 + cells. For this, we used the 4D-Nucleofector technology and an appropriate kit from Lonza. In this condition, plasmid transfection gave a high rate of GFP-expressing cells with high fluorescence intensity ( Figure  2c3 ). On the contrary, transfection of a stabilized EGFP mRNA (Trilink Biotechnologies) gave rise to almost undetectable level of expression (Figure 2c3 ). In order to confirm that the EGFP mRNA was functional, we transfected HEK293T cells with Lipofectamine 2000. More than 20% of the cells expressed the fluorescent protein at a high level (data not shown). This suggested that CD34 + cells were difficult to transfect using synthetic mRNA and the Nucleofector technology. We also tried to transfect the EGFP mRNA using the TransIT-mRNA transfection kit from Mirus Bio, but it failed to efficiently allow GFP expression in CD34 + cells (Supplementary Figure S2b) . Altogether, these results suggested that MS2RLP allowed significant CD34 + hematopoietic cells transduction, even in the absence of cell activation by cytokines.
We further evaluated MS2RLP functionality of MS2-12X-tagged GFP RLP (MS2RLP-GFP) in cell lines. As for the luciferase, GFP was readily detectable, at high efficiency in more than 95% of Hela cells transduced with MS2RLP-GFP (Supplementary Figure S2c) . However, we noticed distinct expression-kinetics, since GFP was detected only 24 hours following transduction and for up to 3 days (Supplementary Figure S2c) . This difference could be due to the low sensitivity in GFP measurements by fluorescence-activated cell sorting (FACS), which would delay detection and to the longer half-life of the protein, which conferred prolonged detectability. 30 As expected, the fluorescence decreased overtime and was cleared at 7 days post-transduction (Supplementary Figure S2c , lower right panel). Lastly, we showed that a single administration of MS2RLPs to human induced pluripotent stem cells (iPS) allowed for efficient Figure S2e) . The fact that the target cells contained a mean of 6 floxable transgenes for the cell population and 13 floxable sites for the clone, implied that one single MS2RLP-Cre delivery was sufficient to excise several loci. The RNAs packaged into MS2RLP do not contain any retroviral sequence involved in the reverse transcription process, which Huh7.5
precluded their DNA conversion following transfer. We thus looked for a possible DNA integration of the Cre recombinase gene in transduced cells. As expected, no signal was detected for MS2RLPs and only ILV-Cre led to integrated copies ( Figure 2e , sample 3 compared to 4). Taken together, our results validated the ability of the MS2RLP packaging system to promote efficient and specific mobilization of biologically active MS2-12X mRNA in all tested cell types.
MS2RLPs deliver subgenomic viral RNAs
We next investigated the mobilization of other types of cytoplasmic RNA with MS2RLPs. Hepatitis C virus (HCV) replicon RNAs, that autonomously replicate by expressing nonstructural viral genes products were used as a model for uncapped RNA. 31 To enable specific mobilization of HCV-replicon RNA, MS2 stem-loop repeats were inserted at the 3' end of the neomycin selection marker coding . 31 Resulting constructs SGR JFH1 -MS2-6X, SGR JFH1 -MS2-12X, and SGR JFH1 -MS2-24X harboring 6, 12, and 24 copies of the MS2 motif respectively, were transcribed in vitro and transfected into Huh7.5 naive cells. Following G418 selection, we obtained resistant clones, except for the GND replication-defective HCV replicon (Supplementary Figure S3a) . 5'UTR-specific RT-qPCR confirmed that G418-resistant Huh7.5 clones harbored HCV RNA and showed comparable replication efficiency (Figure 3b , samples 2-5). To check for MS2-loop loss during HCV replication, RT-PCR primers amplifying the MS2 insertion site were designed and confirmed the stability of the insert (Figure 3c ). Replicon functionality was finally assessed by detection of NS3 and NS5A nonstructural proteins (Supplementary Figure S3b) . Having confirmed that MS2-loop insertion was conserved during HCV replication, we next mobilized the modified replicon by using MS2RLPs. Replicon-harboring Huh7.5 cells were transfected with p8.74 ΔZF_MS2coat or controls and resulting particles were used to transduce naive Huh7. (Figure 3d , sample 5, for the three shades of blue). Interestingly, the mobilization efficiency appeared proportional to the number of inserted MS2 repeats (Figure 3d , sample 5). In transduced cells, specific HCV-RNA RT-qPCR analysis confirmed the efficient replication of HCV RNA (data not shown). As the size of the SGR JFH1 -MS2-24X is approximately 10,000 nt, its recruitment within MS2RLPs suggested that the system could deliver long RNAs. Thus, MS2RLPs were efficient in mobilizing uncapped RNA with an exclusive cytoplasmic replication cycle, such as the HCV genome. Moreover, it indicated that MS2RLPs could be produced in Huh7.5.
Efficient in vivo RNA delivery by MS2RLPs
We next determined whether MS2RLPs enabled systemic and localized in vivo expression in mice. The ability to deliver RNA in vivo would be valuable for several applications in research and the clinic. To ensure the use of purified particles at high titers, an important condition to obtain relevant results in in vivo applications, we used VSV-G pseudotypes (see methods). Among the possible routes for in vivo delivery, two representative modes of injection were evaluated.
First, we checked caudal vein delivery using a purified preparation of MS2RLP (see methods). MS2RLP-Luc (1.7 × 10 11 PP/ml) was employed to determine the kinetics of luciferase expression with systemic injection in mice. A suspension of purified integrative rLV-EF1-Luc vector (2.1 × 10 8 TU/ml) was used as a positive control. Administration by the intravenous route induced a broad diffusion of the bioluminescent signal, which was quantified in the whole mouse body (except the tail signal). At 5 hours after intravenous injection of purified particles, we detected significant luciferase expression (818 relative luminescence units); the signal was still detectable 8 hours postinjection (234 relative luminescence units) and then disappeared at later times (Figure 4a ,b, bottom panels, group MS2RLP-Luc). As expected for caudal vein injection, the bioluminescence signal was predominantly detected in the liver and spleen (Figure 4a ). For comparison, the 5-hour time point measured in animals receiving the purified suspension of integrative rLV-EF1-Luc vector gave a barely detectable signal in the liver and spleen (Figure 4a ). For rLV-EF1-Luc, the signal was significant at 72 hours and almost 7 days (168 hours) were needed to reach the maximum level observed with MS2RLP-Luc (Figure 4b ). These kinetics parallel those obtained in vitro and further emphasized the explosive and brief expression obtained with MS2RLP mRNA delivery as compared to stable lentiviral expression.
To confirm the value of single-shot mRNA delivery, we examined the process with MS2RLP-Cre in ROSA26-YFP reporter mice. 32 We locally injected MS2RLP-Cre (10 7 PP in 5 µl) into the biceps femoris muscle of ROSA26-YFP reporter mice. Injected samples were collected from biceps femoris of five mice 7 days postinjection. As shown in Figure 4c , this model highlighted the efficiency of the nonintegrative MS2RLP-Cre system, which conferred expression of the YFP in a wide zone of injected muscle (Figure 4c , A, B, and C, as compared to nonaffected muscle zone H). MS2RLP-Cre spread in approximately 1 cm of the muscle, and this was comparable to the area reached with a purified integrative rLV-EF1-Cre vector used as a positive control (Figure 4c, E, F, and G) .
33 DLX5 is a member of the distal-less HD protein family and has been implicated in the commitment of mesenchymal progenitors to the osteoblast lineage by the upregulation of RUNX2 and OSTERIX. For RUNX2, we cloned the cDNA variant 1, type II isoform that is predominantly expressed in osteoblasts and is considered essential for osteoblastic differentiation. In a first study, human osteosarcoma MG63 cells, exhibiting an immature phenotype reminiscent of MSCs, 34 were used to assess the biological effect of DLX5 or RUNX2 mRNA transfer. MG63 were transduced with MS2RLP-RUNX2 or MS2RLP-DLX5 (50 × 10 3 or 100 × 10 3
MS2RLPs PP/cell) and cultured with or without the osteogenic differentiation factor BMP4. 35 Retroviral vectors stably expressing the transcription factors were used as positive controls. In the presence of BMP4, and 10 hours after transduction, DLX5 and RUNX2 mRNA transfer induced the endogenous forms of RUNX2 and DLX5 respectively ( Supplementary Figure S4a,b; dark blue) . In cells transduced with MS2RLP-RUNX2 or MS2RLP-DLX5 and without BMP4, the PTHR1 gene showed increased mRNA expression (Supplementary Figure  S4c , dark blue), confirming that MS2RLP RNA delivery could induce transcription of osteoblastic genes.
Next, we examined lineage commitment in highly immature primary human MSC-like cells (MSC-l) 36 not expressing RUNX2. 37 MSC-l cells were transduced twice at 30 hours intervals, with MS2RLP-RUNX2 or MS2RLP-DLX5 (50 × 10 3 MS2RLP PP/cell, see methods). Controls were MSC-l transduced with IDLV-Luc or left untransduced and BMP4-treated, a condition known to consistently differentiate MSCs into functional osteoblasts. 38 At 58 hours post-transduction, endogenous genomic RUNX2 or DLX5 mRNA level significantly increased (Figure 5a ). In addition, the osteoblastic marker integrin-bone sialo-protein (iBSP) was upregulated in both conditions (Figure 5a ). Conversely, the osteoprogenitor master factor OSTERIX showed no change in expression (Figure 5a ), suggesting a commitment of MSC-l toward an early osteoblastic lineage stage.
To complete the study, we analyzed the MSC-l transcriptome following transduction and with IDLV-Luc as a reference. Principal component analysis showed that MS2RLPs expressing RUNX2-or DLX5-mRNA promoted the preferential expression of osteoblastic genes in MSC-l (Figure 5b,c) . However, genes from MS2RLP-DLX5-modified cells were better clustered in the same branch than those from MS2RLP-RUNX2-modified cells (Figure 5d ,e and Supplementary Figure S5 ), suggesting that MS2RLP-DLX5 may be more potent in inducing changes in gene expression. Detailed analysis of significant gene expression changes confirmed the increase in RUNX2, DLX5, and iBSP levels (Supplementary Tables S2 and S3 ). We identified several osteoblastic markers among other upregulated genes, such as PTGS2 and FOSB in MS2RLP-RUNX2 cells and BMP8, VDR, ENPP1, MEIS2 in MS2RLP-DLX5 cells (Figure 5d,e and Supplementary Tables  S2 and S3 ). Interestingly, we confirmed previous observation showing that DLX5 induced RUNX2 whereas RUNX2 failed to induce DLX5 (Supplementary Table S2 ; Supplementary Figure S5a) . 39 In addition, among upregulated genes by MS2RLP-RUNX2, we identified STMN2, a gene induced in adipose and bone marrow-derived stromal cells under pro-osteoblastic differentiation conditions. 40 We confirmed the consistent and early upregulation of STMN2 mRNA expression after BMP4 addition on highly immature mesenchymal stromal-like cells (Supplementary Figure S5b,c) . Finally, we identified a series of common genes with significant expression changes upon MS2RLP-RUNX2 or -DLX5 transfer and BMP4 addition, conditions known to consistently differentiate MSC-I into functional osteoblasts 38 (Supplementary Figure S6a) . Regarding shared upregulated genes in BMP4-induced cells and under the MS2RLP-RUNX2 or -DLX5 condition, the bone/skeletal development process was clearly highlighted by Gene Ontology terms (Supplementary Figure S6b) , especially for MS2RLP-DLX5 and BMP4 conditions (Supplementary Figure S6b) . Overall, MS2RLP-RUNX2 or MS2RLP-DLX5 consistently committed human primary MSC-I toward an early osteoblastic lineage, confirming that MS2RLPs could contribute to promoting cellular reprogramming (Supplementary Tables S4 and S5) .
DISCUSSION
In the present report, we described a versatile and efficient celltransfer system for mRNA or other types of RNAs. Our results showed that exploiting MS2-Coat and its cognate 19-nt stem-loop, led to significant RNA transfer via modified lentiviral particles in all types of cells in vitro or in vivo (Figures 2-5) . As compared to other retroviral platforms, transfer efficiency was high, without any requirement for a selection process 10, 41 (Figures 2-4) . In a therapeutic perspective, an advantage of the MS2RLP system is its ability to utilize lentiviral platforms already validated in clinical settings. Moreover, the RNAs transferred by the MS2RLPs are directly expressed into the cytoplasm, which reduces the risk of integration, an important safety consideration for human use (Figure 2e ). This characteristic is in contrast to transient episomal DNA vectors, such as IDLV, which lead to some integration at low frequency. 42 Although our studies have been performed with lentiviral vectors other retroviruses could be similarly modified. Introducing MS2-Coat sequence within the p12 protein from a gammaretrovirus-derived vector 6 also permitted transfer of RNAs harboring the 19-nt stem-loop (Supplementary Figure S7 ). In addition, like for other vectors, it could be possible to adapt MS2RLPs to a cell type by selecting the envelope exposed at their surface.
The high efficiency of RNA transfer by the MS2RLPs is most likely related to an increased ratio of RNA to particle content, resulting in directly detectable and significant biological activity (Figure 2 ). This is extremely valuable when seeking editing or reprogramming functions, especially if a combination of gene products is required. 43 Additionally, RNAs from MS2RLPs are rapidly bioavailable ( Figures  2b and 4b ), leading to high and short-term expression of the transferred messenger. This characteristic is of great value for genome engineering. In lentiviral transgenesis, the early expression of the transgene following egg-injection is expected to reduce the risk of genome chimerism in the progeny. 44 Short-term and efficient RNA expression would also be valuable in several other applications, such as vaccination and immunotherapy. 45 However, as highlighted by the comparison of the kinetics of expression of luciferase and GFP (Figure 2a ,b compared to c and S2), the half-life of the transferred protein could be a concern as was shown recently with fluorescent proteins. 30 Therefore, the biochemistry of the transferred protein is expected to affect the requirements for designing a useful vector. Several methods could be used to modulate the level of protein expression, including the stabilization of the RNA, with modification of nucleotide usage, 45 or by using defined 5′ and 3′ UTRs.
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For a more sustained expression, viral subgenomic replicons would offer a relevant alternative. Accordingly, we showed MS2RLP-based transfer of an HCV replicon in Huh7.5 cells (Figure 3 ). To build new transfer-platforms, several alternative RNA-replicons exist. Recently, replicons derived from Venezuelan equine encephalitis virus (VEE) and expressing reprogramming genes were shown to support iPS formation. 43 To ensure safety after obtaining the intended biological effect, eradication of the reprogramming replicon is expected and could be triggered by use of cell-fate specific miRNA. 46 Nevertheless, a case-by-case analysis could be useful to evaluate the innate immune response of the target cells, since it could block replication of the replicon. 47 For example, we were unsuccessful in expressing reporter genes from an HCV-replicon transferred by MS2RLP in primary human MSC (data not shown).
MS2RLPs are versatile vectors as demonstrated here by in vitro transfer of mRNAs in cell lines, human iPS, primary human mesenchymal cells and mouse liver or muscles in vivo. While we did not compare MS2RLP to all RNA-transfer methods, our results showed that human primary CD34 + cells, a clinically relevant target not easily transfected using electroporation or chemical transfection, could express high level of a transgene following MS2RLP transduction (Figure 2c and Supplementary Figure S2b) . As for other cell types, CD34 + cells expressed the transgene at a level similar to that reached by IDLV (Figure 2c1-c2 ). Yet, the kinetic was slightly different, MS2RLP giving a higher and faster transgene expression at early time points. Notably, the expression induced by MS2RLP in CD34 + cells was not conditioned by the addition of cytokines. 29 The diversity of RNAs that could be transferred by MS2RLPs is only dictated by the presence of the 19nt MS2 stem-loop. Hence, the molecular structure of transferred RNA is adaptable and amenable to regulation with some tools already available. 7 Here, we have shown that mRNA and RNA-replicon were mobilized ( Figures  1-4) , a property which could no doubt be extended to LncRNA or circRNA as modulators or regulators of gene expression. 48, 49 The transfer of interfering RNAs will need more investigations because the pathway of miRNA maturation involves both nuclear and cytoplasmic steps as well as cleavages, which can separate the recruiting sequence from the active part of the molecule. An aspect we have indirectly explored is the size capacity and limits of the transferred RNA. Our experiments showed that the short GFP sequence and HCV replicon, of approximately 10 kb (Figures 2 and 3) , could be transferred efficiently. This covers most of the needs in the field of RNA transfer. Similarly, by recruiting the RNA independently of dimerization ( Figure 1 ) and with more than four molecules per particle (Supplementary Figure S1b) , MS2RLPs should permit the cotransfer of different species of RNA. For the reprogramming experiments, several different osteogenic factors could be used, and the opportunity to sequentially deliver these factors through MS2RLPs might be very valuable. Among potential applications are gene-editing methods. 3 The opportunity to get highly efficient Cre recombinase activity after mRNA MS2RLP delivery ( Figures  2d and 4c) paves the route to transfer of other systems such as those based on CRISPR/Cas (a preliminary experiments is given in Supplementary Figure S2f) . 3 For the transfer of the CRISPR/Cas9, the multiplexing of several species of RNAs, one coding Cas9 and others the sgRNA, would be needed. Moreover, it will be a complex challenge to obtain optimal stoichiometry following encapsidation of the different RNA species into the same particles.
Considering in vivo applications, our results further illustrate the efficacy of MS2RLPs for the delivery of genetic information. For vaccination, besides the expression of immunogenic proteins by RNAs, immune response could be improved by transferring subgenomic replicons. Expressing viral nonstructural genes could contribute to the clearance of cells infected by the native virus. By mobilizing an HCV replicon from Huh7.5 cells (Figure 3) , we showed that MS2RLPs were also compliant in terms of production and could be eligible for in vivo local production of vaccinating particles. 50 In the mouse muscle in vivo, Cre expressing MS2RLPs allowed for a spread of the excision over 1 cm (Figure 4c ). Such diffusion is broad and equivalent to that obtained with direct injection of nonenveloped vectors such as adeno-associated virus-based vectors. 51, 52 Systemic injection, while it mainly directs the vector load in the liver and spleen (Figure 4) , offers a relevant alternative to delivering active RNAs. As mentioned above, organ specificity could be addressed by choosing the most adapted cell-penetrating envelope.
We also applied the system in a cell therapy approach, primary MSC-l ( Figure 5 and Supplementary Files). Our data confirmed that transfer of bone specific transcription factor via MS2RLPs promoted osteogenesis induction ( Figure 5 ). However, the protocol evaluated here proved to be limited to the priming of the MSC-l. We nevertheless identified OSTERIX, STMN2 and other genes as possible targets to trigger a more profound fate-shift toward the osteoblast phenotype. There is currently no definitive recipe to achieve this process in culture. 53 Adapting MS2RLPs to high-throughput screening procedures will help to identify key factors and protocols for controlled administration of selected genes.
In conclusion, thanks to high titers on primary cells as well as in vivo, the new MS2RLPs described here, offer a significant and important alternative in the field of RNA delivery. Because of their versatile nature in packaging various types of RNAs, MS2RLPs have broad potential for application, including stem cell-differentiation, immunotherapy and genome editing.
MATeRIAlS AND MeTHODS

Packaging vector and plasmid expression constructs
HIV-I-derived MS2RLP. An MS2 containing HIV-I-derived vector was generated by substituting the NC's second zinc finger (ZF2) domain with the MS2 coat protein. The ZF2 domain was removed from p8.74 lentiviral plasmid using assembly PCR. The upstream region of the deletion site was amplified by using P8.74bZF-for: CCgCggCCgCgTTgACgCgCA (containing a Not-I site) and P8.74bZF-rev: CAgTgTTAACgCCCTTTTTCCTAgg (containing a HpaI restriction site). The downstream region of the deletion site was amplified using P8.74aZF-for: ATgCggCCgCgTTAACACTgAgAgACAgg (with a Not-I site) and P8.74aZF-rev: ggCTgATATCTAATCCCTggTgTCTC (containing a EcoRV site). After subcloning into PGEMT-easy plasmid, vectors were NotI/EcorV digested and reassembled into NotI/EcoRV digested p8.74 plasmid to generate p8.74∆ZF vector (ΔZF). The MS2 Coat protein coding sequence was amplified from LMNI-MS2-NLS-GFP plasmid, kind gift of P.D Bieniasz (Aaron Diamond AIDS Res. Center, New York), using HpaI containing primers MS2Coat-HpaI-for: TTgTTAACATggCTTCTAACTTT, and MS2Coat-HpaI-rev: CCgTTAACgTAgATgCCggAgTT and was inserted into p8.74∆ZF digested by HpaI leading to an in-frame cloning and generating p8.74 ∆ZF_MS2Coat (ΔZF_MS2coat) Coat vector (Figure 1) .
Engineering mRNA. To enable the mobilization of mRNA into lentiviral particles, 12 repeats of the MS2 stem-loops were inserted into the expression vector pcDNA3.1 (Life Technologies SAS, Saint Aubin, France) containing the luciferase gene reporter. PCR and specific primers were used to obtain the entire luciferase Firefly sequence by PCR (Table 1) , which was cloned into pcDNA3.1(-) vector (Life Technologies SAS) at the HindIII and KpnI sites to generate pcDNA-luciferase (pLuc). To generate pcDNA-luciferase-MS2-12X (Luc_MS2_12X), fragment containing 12 repeats of MS2 was obtained by digestion of pGemTeasy-MS2-12X plasmid with BamHI. The obtained fragment was blunted with DNA polymerase I large (Klenow) fragment (5,000 units/ml; New England Biolabs, Evry, France) and inserted into 3' of luciferase gene in pcDNA-Luc plasmids previously digested with KpnI and treated with DNA polymerase I large (Klenow) fragment (Figure 1) .
In parallel, a pcDNA-EF1-Cre-MS2_12X plasmid was generated. To construct this vector, a pCMV-luciferase sequence was deleted from the pcDNA-luciferase-Vimentin-MS2_12X vector and substituted by a pEF1-Cre sequence amplified from a previous construct. The plasmid was generated by using the In-Fusion HD cloning kit (Clontech Laboratories). To avoid recombination, MS2 stem-loops-containing plasmids were grown at 32 °C.
For integrative and integrative-deficient lentiviral vectors, we used three different self-inactivating expression vectors, pLV-EF1-GFP, pLV-EF1-Luc, and pLV-EF1-CRE, based on the backbone described by Dull et al. 26 These vectors encode the GFP, the luciferase or the CRE recombinase, respectively under control of the human elongation factor 12α promoter (EF1a). Official journal of the American Society of Gene & Cell Therapy motif were amplified by using MS2-BamHI-for: ACCCgggCCCTATATATggATCC forward primer and the reverse primers MS2-BamHI-6X-rev: ATggATCCgTgATTCCCCg or MS2-BamHI-12X-rev: TAggCAATTAggATCCTTAggAT containing BamHI restriction site. Resulting PCR products were sub-cloned into pGEMT-easy vector. MS2 repeats harbouring pGEMT constructs were then BamHI-digested, Klenow treated, and inserted into pSGR-JFH1-Neo subgenomic replicon coding plasmid at the PmeI restriction site ( Figure 3) . As above, MS2 stem-loops-containing plasmids were grown at 32 °C.
Viral vector production and quantitation
Amphotropic pseudotyped lentiviral particles. Productions were performed in 293T cells (ATCC CRL-11268) seeded at 4.2 × 10 6 cells per plate into a 10-cm dish and grown overnight in Dulbecco's modified Eagle medium (DMEM) Glutamax (Life Technologies, Carlsbad, CA) supplemented with 10% heatinactivated fetal calf serum, 100 µg/ml Stretomycin, 100 U/ml Penicillin and placed at 37 °C in a humidified atmosphere of 5% CO 2 in air. Fugene 6 transfection reagent was used to transfect cells with 1 µg p8.74ΔZF-MS2-coat, 1 µg of pCMV-Env encoding 4070A amphotropic envelope, 80 ng pEGFPC1 for normalization and 2.52 × 10 −13 mole of Luc_MS2_12X. After 8 hours, the medium was removed and cells were washed with phosphate-buffered saline (PBS), then fresh medium was added. After 48 hours, particles-containing supernatants were harvested and filtered through a 0.45-µm pore filter (Millipore, Saint Quentin en Yvelines, France).
VSV-G-pseudotyped lentiviral particles.
Productions were performed in a 10-layer CellSTACK (6,360 cm 2 , Corning) using 293T cells. The tri-transfection mix was composed of three plasmids: pENV carrying the VSVG envelope, p8.74 (WT) or p8.74 ΔZF_MS2coat or p8.74 mutated in the D64L to produce (IDLV), and pLV-EF1-cDNA/pMS2-cDNA. Twenty-four hours post-transfection by standard calcium phosphate procedure, the supernatant was discarded and replaced by fresh nonsupplemented DMEM. Cells were incubated at 37 °C in a humidified atmosphere of 5% CO 2 in air. After medium change, the supernatant was collected. Fresh nonsupplemented DMEM was added and the cells were incubated prior to further harvest. Each harvest was clarified by centrifugation for 5 minutes at 3,000g before being microfiltered through a 0.45-µm pore-size sterile filter unit (Stericup, Millipore). The whole set of harvest were then pooled to supply the crude harvest.
Viral vectors concentration and purification.
The crude harvest was first concentrated by tangential flow ultrafiltration with polysulfone hollow-fiber cartridges. The supernatant was then diafiltered against DMEM buffer, and retentate was recovered and further concentrated on ultrafiltration disposable units.
Functional particle quantification by qPCR. Transduction unit titration assays were performed as follows. HCT116 cells were seeded in 96-well plate in 100 µl of DMEM supplemented with 10% heat-inactivated foetal calf serum, 100 µg/ml Stretomycin, 100 U/ml Penicillin. Twenty-four hours later, five serial dilutions were performed with each vector sample and an rLV-EF1-GFP internal standard. The cells were transduced in presence of 8 µg/ml Polybrene (Sigma). For each sample series, one well of nontransduced cells is added as control. Three days post-transduction, cells were trypsinized and the titer (transducing units/ml) was determined by qPCR after extraction of genomic DNA using the Nucleospin tissue gDNA extraction kit (Macherey-Nagel, Hoerdt, France). The titer determined in transducing units per ml (TU/ml) using qPCR was normalized by an internal standard whose titer was previously determined by FACS.
Physical particle quantitation by p24 ELISA. The p24 core antigen is detected directly on the viral supernatant with use of a HIV-1 p24 ELISA kit (Perkin Elmer, Courtaboeuf, France). The reaction is based on an antigen capture recognized with a biotinylated polyclonal antibody against HIV-1 CAp24. The resulting complex is revealed by a streptavidin-horseradish peroxidase conjugate after incubation with ortho-phenylenediamine-HCl, producing a yellow colour proportional to the amount of CAp24 captured. The absorbance of each well is measured; quantification is obtained as compared to a standard curve established with reference HIV-1 CAp24 antigen samples, on a microplate reader. The viral titer expressed in physical particles per ml is calculated from the amount of p24 knowing that 1pg of p24 corresponds to approximately 10 4 physical particles.
Quantitative real-time RT-qPCR. To assess mRNA mobilization into lentiviral particles, RNA was extracted from 140 µl lentiviral particles containing supernatants by use of the QIAamp viral RNA Mini-kit (Qiagen, Courtaboeuf, France). In total, 4 µl RNA treated with TURBO DNAse (2 U/µl) was used for cDNA synthesis with the Superscript First-strand Synthesis System (Life Technologies). Luciferase RNA copies were quantified by RT-qPCR, with a Light Cycler480-II system (Roche, Boulogne-Billancourt, France). RT-qPCR amplification: 2 µl of reverse transcriptase product, 1× SYBR Green I master mix (Roche), 10 µmol/l of each primer and RNase-free water to a final volume of 20 µl was quantitated by 5-minute preamplification at 95 °C, 45 cycles: 10" at 60 °C and 10" at 72 °C, followed by melting curve and cooling steps. PCR amplification was obtained with primers allowing specific amplification of the luciferase, forward, 5′-CAACTgCATAAggCTATgAAgAgA-3′ and reverse, 5′-ATTTGTATTCAgCCCATATCgTTT-3′. The RNA copy number was calculated by an external standard curve of serial dilution of a pBullet-Luc plasmid.
Quantitative real-time RT-qPCR on serial dilution. Since the CAp24 normalization could be someway misleading, we designed an unbiased experiment to estimate MS2RLP RNA-content. Supernatant from cells producing the MS2RLP or a standard lentiviral vector (ILV) were serially diluted, six serial one-half dilutions from crude supernatant, and the amount of RNA per sample was measured by RT-qPCR (see above for RT-qPCR). From the data, we draw a curve and derived their respective equation (Supplementary Figure S1b ). The curves are theoretically expected to converge to the intercept and their respective slopes are proportional to the amount of RNA per particle. The ratio calculated using MS2RLP slope over ILV slope gives the factor of difference in RNA content between the two types of particles, independently of the structure of the particles. The experiments were repeated independently three times in triplicate.
Electron microscopy
Transmission electron microscopy was performed at IMPMC (UMR 7590, CNRS-UPMC-IRD-MNHN, Paris, France). For negative staining, samples produced at about 10 12 PP/ml were diluted 50-fold and 5 μl were dropped onto plain carbon grids, blotted, and immediately stained for 1 minute with 5 μl of 2% uranyl acetate before blotting again. The sample was allowed to dry before observation under a LaB6 JEOL JEM2100 electron microscope (×52,800 magnification). Data were digitally recorded by use of a 2k × 2k Gatan camera.
Luciferase assay and luciferase kinetics
On the day before transduction, 60,000 293T cells were seeded in 96-well plate. The day of transduction, test samples of MS2RLP were applied to cells with or without 3 µg/ml puromycin. This translation inhibitor was added 1 hour before transduction. For 4070A envelopes transduction was realized in presence of Polybrene (5 µg/ml, Sigma-Aldrich, Saint Quentin Fallavier, France) and under centrifugation for 1 hour at 1,900 rpm and 37 °C. Following transduction, luciferase expression was determined by use of the Bright-Glo luciferase assay (Promega, Charbonnières-les-Bains, France) and a Centro LB 960 luminometer (Berthold Technologies). The assay was performed in triplicate.
For the kinetics, HCT116 cells were seeded in six-well plate and incubated 24 hours at 37 °C in 5% CO 2 . Transduction by ILV, IDLV, or MS2RLP was carried out in presence of 4 µg/ml Polybrene with 2 × 10 5 physical particles/cell. The transduction-supernatant is removed 5 hours later. From 4-24 hours posttransduction, cells were harvested and luciferase expression was analyzed using the One-Glo Luciferase assay (Promega) as above. The assay was performed in triplicate. cytokines (Peprotech), including hSCF (100 ng/ml), hTPO (100 ng/ml), hFLT3L (100 ng/ml), and hIL3 (60 ng/ml).
Cre recombinase in vitro
The nonintegrative GFP vector (IDLV-GFP) supernatant was produced by transient transfection of HEK293T cells in 10-cm dishes, using Fugene 6 (Promega). Plasmids were a self-inactivating (SIN) and Tat-independent lentiviral vector encoding GFP under the control of the EF1α promoter/enhancer (LTGCEGFP1), and three packaging plasmids including HPV275D64A (HIV1 gag/pol with a D64A mutation in integrase), p633 (expressing rev), and ΨN15 (VSVG). 54 IDLV supernatants were collected 48 hours after transfection, filtered through a 0.45-µm filter, concentrated ≈1,000-fold by ultracentrifugation and stored at −80 °C; ELISA CAp24 concentration was 13.4 ± 0.4 µg/ml.
The GFP RNA vector (MS2RLP-GFP) was produced by transient transfection of HEK293T cells in 10-cm dishes, using Fugene 6. Plasmids transfected consisted of the GFP encoding plasmid pVAX2-EGFP-MS2-12X, and three packaging plasmids including p8.74_ΔZFMS2Coat, p633 (rev) and ΨN15 (VSVG). pVAX2-EGFP-MS2-12X was made by subcloning EGFP-MS2-12X from pBullet-EGFP-MS2-12X in pVAX2. It encodes EGFP under the control of the Human cytomegalovirus immediate-early (CMV) promoter and has a bovine growth hormone polyadenylation signal. pVAX2 was obtained by replacing the cytomegalovirus promoter of pVAX1 (Life Technologies) by that of pCMVβ (Takara), as described. 55 VLP supernatants were collected 48 hours after transfection, filtered through a 0.45-µm filter, concentrated ≈1,000-fold by ultracentrifugation and stored at −80 °C; ELISA CAp24 concentration was 27.4 ± 3.2 µg/ml.
The GFP mRNA was obtained from Trilink Biotechnologies. It carries an antireverse cap analog at the 5' end, it is polyadenylated, and is modified with 5-methylcytidine and pseudouridine to decrease nuclease activity and Toll-like receptor activation, mimicking a fully processed mature mRNA. Transfection used the 4D-Nucleofector X Unit and the P3 Primary Cell 4D-Nucleofector X Kit (Lonza) or the TransIT-mRNA Transfection kit (Mirus Bio). A control plasmid expressing GFP (pmaxGFP) is included in the Nucleofector X kit. 
Transduction of human induced pluripotent stem cells
The BBHX8 hiPSC line was maintained on Matrigel-coated culture wells (BD Biosciences, San Jose, CA) in mTeSR1 (Stemcell Technologies, Vancouver, BC, Canada) at 37 °C in 5% CO 2 incubator with daily medium change and by using Gentle Cell Dissociation Reagent (Stemcell Technologies) for cell passaging. Three days before transduction, 200 × 10 3 cells were seeded in 12-well plate. Transduction was performed for 24 hours with different amount of viral particles, in ng of CAp24, and with cells at 60-70% confluence. Before FACS analysis, cells were detached using TrypLE (Life Technologies).
HCV RNA in vitro transcription
After XbaI linearization of plasmids, modified and control HCV replicons RNAs were synthetized in vitro by transcription using RiboMAX large-scale RNA production system T7 (Promega). After DNAse treatment, RNAs were purified with RNA clean-up kit (Macherey-Nagel) before transfection.
HCV RNA transfection and quantitative real-time PCR
In vitro synthetized HCV replicons, RNAs were transfected into Huh7.5 cells by electroporation: trypsinized cells were washed in PBS, and 2 × 10 6 cells were resuspended in 1 ml PBS and placed in 0.4-cm electroporation cuvettes (Biorad). Electroporation with a 950 μF and 260 V pulse in a Genepulser system (Biorad). After electroporation, cell suspension was transferred in 10-cm plates containing medium and incubated at 37 °C under standard conditions. Two days after transfection, cells were selected with 1 mg/ml geneticin.
Total RNAs from transfected Huh7.5 and Huh7.5 HCV were extracted (Nucleospin RNAII kit, Macherey-Nagel), and 0.5 µg of RNA was used for cDNAs synthesis (Super-Script First-Strand II Synthesis System, Invitrogen). JFH1 RNA quantification was performed by qPCR with JFH1 and β-actinspecific primers (Supplementary Table S1 ) using SYBRGreen incorporation (SYBRGreen I MASTER). Cycling conditions were 5 minutes preamplification at 95 °C, 45 cycles (10" 95 °C, 10" 60 °C, 10" 72 °C) (Light-Cycler-480-II, Roche).
MS2RLP-HCV production and colony formation assay
For HCV replicon RNA mobilization, 2.5 × 10 6 Huh7.5 HCV cells harboring JFH1-derived subgenomic replicons were transfected using FuGENE-6 (Promega) with 1.5 µg Gag-Pol coding plasmids, 1 µg of pCMV-Env Ampho plasmid. Supernatant from transfected cells were harvested and filtered (0.45-µm filters, Millipore) at 24, 36, 48, and 60 hours post-transfection. Naive Huh7.5 was transduced using 2 ml of filtered supernatants. Transduction was facilitated by 45 minutes spinoculation at 1,200 × g with 5 µg/ml polybrene (Sigma-Aldrich). Transduced cells were selected in 1 mg/ml geneticin 48 hours after transduction. Resistant clones were fixed in 2% paraformaldehyde, crystal violet stained and counted, using ImageJ cell counter pluggin. Results were obtained from four independent experiments performed in duplicates. After transduction, some clones were expanded forfurther analysis, by HCV RNA-specific RTqPCR or western blotting.
Bioluminescence kinetics in mice In vivo YFP expression in ROSA 26 YFP reporter mice after injection of MS2RLP-Cre or rLV-EF1-Cre Eleven ROSA 26 YFP reporter mice 32 were injected with ILV EF1a CRE (n = 5), MS2RLP (ARN) CRE (n = 5), or PBS (n = 1). Mice were anesthetized by continuous inhalation of 1.5% Isoflurane in O 2 -enriched air. A 5-mm incision of the skin above the left thigh was performed to visualize the biceps femoris. Five microliters of concentrated vectors or PBS were manually injected in a single injection site in the bicept femoris. The total dose injected corresponded to 3 µg of CAp24 and 0.5 µg for MS2RLP (ARN) CRE and ILV EF1a CRE vectors respectively. At 7 days after injection, the complete left thigh of mice were removed and fixed overnight in 4% paraformaldehyde in 1× PBS. Fixed tissues were cryoprotected in 15% sucrose in 1× PBS for 48 hours, frozen at −50 °C in isopentane and sliced in 20-µm-thick sections. The section axis was parallel to the global orientation of muscle fibers in the biceps femoris. YFP expression was observed after immunostaining as described previously 56 with rabbit anti-GFP primary antibody (1:1,000; Molecular probes) and Alexa-fluor 488 goat anti-rabbit IgG as secondary antibody (1:1,000; Invitrogen). Nuclei were stained with Hoechst 33342. Photographs of whole sections were acquired with a Hamamatsu NanoZoomer scanner (20× resolution) and enlargement of selected areas were photographed with a Leica DM5000 epifluorescent microscope equipped with a Leica color camera. mRNA transfer study in primary bone marrow cells mesenchymal stem cells
MSCs transduction with lentiviral particles. The study involved human bone marrow cells isolated from femoral heads from four healthy volunteers undergoing orthopaedic surgery. The study followed the ethical guidelines of the University Hospital of Tours (Tours, France) and was approved by the ethics committee Comité de protection des personnes (Tours -Région Centre (Ouest-1)). Cells were cultured in endothelial growth medium 2 (Promocell, Heidelberg, Germany) for 14 days. Three days before the transduction, cells were seeded in 12-well plates at 5,000 cells/cm 2 Official journal of the American Society of Gene & Cell Therapy and cells were cultured in αMEM (Minimum Essential medium) supplemented with 2% fetal calf serum. After 12 hours, medium was removed and replaced. Thirty hours after the first transduction, cells were transduced again as above. At 10 and 58 hours, cells were washed three times with PBS and harvested.
RNA extraction. Total RNA was extracted with RNeasy microkit (Qiagen) including a DNAse treatment. Extracted RNA was eluted in 15 µl RNase-free water. RNA concentration and quality was determined with Experion Automated Electrophoresis System (BioRad, Marnes-la-Coquette, France) and Nanodrop spectrophotometer (Thermo Scientific).
Real time qPCR. First-strand cDNA was prepared using the High capacity reverse transcription kit (Applied Biosystems, Saint Aubin, France) with 100 ng total RNA and random primers. The expression of osteoblastic transcription factor RUNX2, DLX5, iBSP, and OSTERIX was evaluated by real-time quantitative PCR with EvaGreen incorporation (SsoFast EvaGreen kit, CFX96 Real-time PCR detection system, Biorad). PCR reaction: 4 µl of reverse transcriptase diluted at 2:1 in RNAse-DNAse-free water, 1× SsoFast EvaGreen kit, 10 µmol/l of each primer and RNase-free water to a final volume of 10 µl. Three minutes preamplification at 95 °C, 40 cycles of 10" at 95 °C and 30" at 60 °C. The PPIA gene was used as a normalization control.
cDNA microarray analysis. Double-stranded cDNAs were prepared from 25 ng of total RNA with ovation PicoSL WTA system v2 kit (Nugen Leek, The Netherlands). The fragmented end-labeled cDNA was hybridized to GeneChip Human Gene 1.1ST array strip (Affymetrix, High Wycombe, UK) for 20 hours at 48 °C. After hybridization, the chips were stained and washed in a GeneChip Fluidics Station 450 (Affymetrix) and scanned using a GeneChip Array scanner (Affymetrix). The raw file generated contained expression intensity data and was used for analysis.
High-throughput studies. Principal component analysis was performed for global unsupervised analysis. Supervised analyses for generation of each specific gene expression signature were obtained by using of Partek Genomics Suite software with the sample-paired t-test that matched each donor treatment. Gene expression signature was carried out for fold changes in expression > |1.2|, P < 0.05. Differentially expressed genes were hierarchically clustered using the TM4 Microarray Software Suite 57 with the Euclidian distance metric and average linkage method. Clustering and heatmaps involved TM4 Software Suite. Gene expression data with log values < 3 were not considered. Differential expression analysis involved a linear model with an empirical Bayes method to moderate the standard errors of the estimated log ratio changes. ConsensusPathDB-human (http://cpdb.molgen.mpg.de) served for functional annotation analysis with gene ontology terms. 58 Venn diagrams were obtained with http://bioinformatics.psb.ugent.be. The Gene Set Enrichment Analysis 59 (GSEA Broad Institute, Cambridge, MA) software was used for analyzing the median t-test of MS2RLP-RUNX2 or MS2RLP-DLX5 to the IDLV-Luc control, with a home-made gene list of osteoblastic markers.
Statistical analysis
Data from three or four independent experiments in triplicate were analyzed. Data are expressed as mean−SD; Wilcoxon-Mann-Whitney was used to analyze the data.
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